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Abstract. Breast cancer is a leading cause of cancer-related 
mortality among women. Altered fucosylation was found to be 
closely associated with tumorigenesis and metastasis of breast 
cancer. MicroRNAs (miRNAs) are important regulators of cell 
proliferation and metastasis, and aberrant miRNA expression 
has been observed in breast cancer. The present study aimed 
to evaluate the level of fucosyltransferase IV (FUT4) and 
miR-493-5p in breast cancer and investigate their relationship. 
In the present study, we demonstrated the differential expres-
sional profiles of FUT4 and miR‑493‑5p in 29 clinical breast 
cancer tissues, matched adjacent tissue samples and two breast 
carcinoma cell lines (MCF-7 and MDA-MB-231). Briefly, 
altered expression levels of FUT4 modified the invasive activi-
ties and tumorigenicity of the MCF-7 and MDA-MB-231 cells. 
Further study demonstrated that miR-493-5p plays a role as a 
suppressor in breast cancer cell invasion and tumorigenicity. 
Moreover, the expression levels of miR-493-5p were inversely 
proportional to those of FUT4 both at the mRNA and protein 
levels. Luciferase reporter assays confirmed that miR‑493‑5p 
bound to the 3'-untranslated (3'-UTR) region of FUT4, and 
inhibited the expression of FUT4 in breast cancer cells. Taken 
together, our data suggest that FUT4 may have a potential role 
in the treatment of breast cancer, as well as miR-493-5p is a 
novel regulator of invasiveness and tumorigenicity of breast 
cancer cells through targeting FUT4. The miR-493-5p/FUT4 
pathway has therapeutic potential in breast cancer.
Introduction
Breast cancer is the most common invasive cancer and the 
second cause of cancer-related death in women (1,2). Each year 
more than a half a million new cases of breast cancer are diag-
nosed in the US and Europe (3), and in China. Breast cancer 
is a very heterogeneous disease. Some patients are cured by 
the surgical removal of the primary tumor while other patients 
suffer from metastasis and progression of the disease, despite 
adjuvant therapy. Therefore, it is essential to develop effective 
and safer therapeutic modalities against breast cancer.
Glycosylation is one of the important steps of protein 
post‑translational modifications, and ~50% of proteins are 
glycosylated (4). Protein glycosylation plays a role in a 
variety of cellular biological functions, such as cell-cell and 
cell-substrate adhesion, membrane organization, cell immu-
nogenicity and protein targeting (5). Specific changes in the 
glycosylation patterns of cell surface glycoprotein have been 
shown to enhance the metastatic potential of tumor cells. 
Aberrant expression of fucosylated glycans has also been 
detected in various types of tumors.
The fucosyltransferase (FUT) family is a group of fucosyl-
ation synthases that catalyze the transfer of L-fucose (Fuc) 
from an activated GDP-β-L-Fuc to various acceptor molecules 
such as N-acetyllactosamine. The transfer of Fuc residue from 
the donor substrate, GDP-Fuc, is catalyzed to the oligosac-
charide acceptor in a1,2-(FUT1 and FUT2), a1,3/4-(FUT3, 
FUT4, FUT5, FUT6, FUT7, FUT9, FUT10 and FUT11) and 
a1,6-linkage (FUT8). Frequent fucosylation, the final step 
within the glycosylation machinery, results in glycans that 
are involved in various cellular processes such as cell-cell 
recognition, adhesion and inflammation or tumor metastasis. 
Fucosylation is suggested to have paramount importance in the 
invasion and metastatic process of cancer stem cells (CSCs) (6), 
for example increasing FUT4 and FUT7 expression promoted 
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neoplastic cell proliferation and hepatocellular carcinoma cell 
growth in vitro, respectively, and reducing FUT3/6 expression 
suppressed colon carcinoma cell proliferation (7,8).
MicroRNAs (miRNAs) comprise a class of small non-
coding RNAs implicated in post-transcriptional RNA 
regulation. These RNA molecules are ~22 nt in length (9). 
By binding to complementary sequences in the 3'UTRs of 
targeted mRNAs, miRNAs degrade or inhibit their translation 
and regulate a range of cellular functions such as differentia-
tion, proliferation, apoptosis and migration of tumor cells (10). 
Accumulating evidence demonstrates that various types of 
miRNAs participate in the regulation of tumorigenesis and 
metastasis (11,12). Recent studies support the assumption that 
modulating the levels of miR-146a or miR-146b could have 
therapeutic potential to suppress breast cancer metastasis (13). 
It was reported for the first time that anti‑miR‑17 molecules 
reduced breast cancer cell migration in vitro and metastasis 
in vivo (14). miR‑184 was identified as a putative breast tumor 
suppressor in pubertal mouse mammary gland (15).
In the present study, we evaluated the expression level of 
the FUT4 gene in the MCF-7 and MDA-MB-231 cell lines 
and clinical breast cancer samples. We also investigated 
whether FUT4 participates in the regulation of tumor inva-
sion and tumorigenicity. In addition, the present study aimed 
to determine the association between miR-493-5p and FUT4 
in human breast cancer, in order to provide a better under-
standing of the mechanisms underlying breast cancer invasion 
and tumorigenicity.
Materials and methods
Cell culture. Cell lines MDA-MB-231 and MCF-7 were 
obtained from KeyGen Co. (Nanjing, China) and cultured 
in Dulbecco's modified Eagle's medium (DMEM), 10% fetal 
bovine serum (FBS) and 1% penicillin‑streptomycin (both 
from Gibco, Grand Island, NY, USA) at 37˚C in a humidified 
atmosphere under 5% CO2.
Patient tissue collection and RNA extraction. Twenty-nine 
breast cancer and matched adjacent tissue samples were 
resected from patients at the Second Affiliated Hospital of 
Dalian Medical University (Dalian, China) from July 2011 
to June 2014. Informed consent forms and the entire protocol 
were approved by the Ethics Committee of the Second 
Affiliated Hospital of Dalian Medical University. The samples 
were stored at ‑80˚C, and total RNA was extracted with TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA).
Quantitative real-time PCR analysis. The concentration and 
quality of each total RNA sample was determined using A260/
A280 spectrophotometric reading. cDNA was synthesized 
with TaqMan reverse transcription reagents (Applied 
Biosystems, Branchbury, NJ, USA), following the manufac-
turer's recommendations. Real-time PCR was carried out 
using 7500 Fast Real-time PCR system (Applied Biosystems). 
Reactions were run in 3 independent experiments. The relative 
expression level of FUT4 was normalized to GAPDh. The 
primer sequences were: 5'-TCCTACGGAGAGGCTCAG-3' 
and 5'-TCCTCG TAGTCCAACACG-3'. RT-PCR for 
miR-493-5p was performed using Real-Time PCR Universal 
Reagent (GenePharma, Shanghai, China). U6 was used as an 
internal control.
Western blot analysis. Protein was extracted from the cells 
using 1X radioimmunoprecipitation assay lysis buffer (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), subjected to 
SDS‑PAGE, and then transferred to polyvinylidene difluoride 
membranes. The membranes were blocked in 5% skimmed 
milk for 2 h, probed with the antibody against human FUT4 
(1:1,000 dilution; Abcam, Cambridge, UK) or GAPDh (1:1,000 
dilution) at 4˚C overnight, and with peroxidase‑conjugated 
secondary antibody (1:1,000 dilution) (both from Santa Cruz 
Biotechnology), and then visualized by chemiluminescence 
(GE Healthcare, Fairfield, CT, USA).
In vivo tumorigenesis. All animal experiments were performed 
according to the protocol of the Dalian Committee on Animal 
Care using 5- to 6-week-old male athymic nude mice. Cells 
(1x107) were subcutaneously injected into the right flank of 
each nude mouse. The length (L) and width (W) of each tumor 
were measured every 7 days with calipers, and the volume was 
calculated.
Lentivirus production and infection. The FUT4 coding 
sequence (CDS) was obtained and inserted into the NotI and 
BamhI sites of the pGLV5/h1/GFP+Puro lentiviral plasmid, 
respectively. The FUT4 shRNA sequences were inserted into 
the BamhI and EcoRI sites of the pGLV3/h1/GFP+Puro lenti-
viral plasmid. Lentiviral plasmids were co-transfected with 
PG-P1-VSVG, PG-P2-REV and PG-P3-RRE plasmids into 
293T cells (Invitrogen), and virus-containing supernatants 
were prepared according to the manufacturer's instructions. 
For the lentiviral infection, the cells cultured in 6-well tissue 
culture plates were infected with the lentiviral vectors at a 
multiplicity of infection of 40 for 24 h. The medium was 
replaced with fresh complete medium. After 2 days, the 
cells were observed by fluorescence microscopy to confirm 
that >90% of the cells were GFP‑positive. Subsequently, the 
GFP-positive cells were screened by addition of 5 µg/ml 
puromycin.
In vitro ECM invasion assay. Cell invasion was assessed using 
the Matrigel invasion chamber (Corning, Corning, NY, USA) 
in triplicate. The cells (1.0x105) were harvested in serum-free 
medium containing 0.1% BSA and plated to the upper chamber 
precoated with Matrigel. Medium containing 10% FBS in the 
lower chamber served as the chemoattractant. After the cells 
were incubated at 37˚C in a humidified incubator with 5% CO2 
for 24 h, the non-invading cells were removed with cotton 
swabs. The invasive cells that had attached to the lower surface 
of the inserted membrane were fixed in 100% methanol at room 
temperature and stained with Wright-Giemsa. The number of 
invasive cells on the lower surface of the membrane was then 
counted under a microscope.
Luciferase reporter assay. A pmirGLO Dual-Luciferase 
miRNA target expression vector was used for 3'UTR 
luciferase assays (Promega, Madison, WI, USA). The target 
genes of miRNA-493-5p were selected based on target 
scan algorithms (microRNA.org (http://www.microrna.
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org/microrna/home.do), MicroCosm (http://www.ebi.
ac.uk/enright-srv/microcosm/htdocs/targets/) and TargetScan 
(http://www. targetscan. org/). For 3'UTR luciferase assay, 
the cells were co-transfected with hsa-miR-493-5p mimics 
or pmirGLO Dual-Luciferase miRNA target expression 
vectors and the wild-type or mutant target sequence using 
Lipofectamine 2000. Luciferase assay was performed using 
the Dual-Luciferase® reporter assay system (Promega) after 
transfection at 48 h. Data are presented as the mean value ± SD 
for triplicate experiments.
Statistical analysis. Statistical analyses were carried out using 
the SPSS 17.0 program. An independent sample t-test was run 
to analyze the significance of the differences found. P‑value 
<0.05 was considered to indicate a statistically significant 
result. All data are presented as the mean ± SD.
Results
Expression of FUT4 in human breast cancer cell lines and 
tissues. We first determined the expression of FUT4 in breast 
cancer cell lines, primary breast cancer and the matched 
adjacent tissue samples. As shown in Fig. 1A and B, the 
FUT4 (5.76‑fold) expression level was significantly higher in 
the MDA-MB-231 cell line than that in the MCF-7 cell line. 
Furthermore, analysis of FUT4 expression in pairs of the 
primary breast cancer and matched adjacent tissue samples 
revealed that FUT4 was upregulated in the primary breast 
cancer tissue samples (Fig. 1C and D). These data support the 
assumption that the differential expression of FUT4 may be 
associated with breast cancer.
Effect of FUT4 overexpression or silencing on the invasive 
ability and tumorigenicity of breast cancer cells. To test 
whether FUT4 plays a role in regulating invasion, we infected 
MCF-7 cells with lentiviral vectors containing FUT4. After 
infection, the MCF-7/FUT4 cells expressed high exogenous 
FUT4 (Fig. 2A and B) in comparison with the uninfected 
controls or GFP-expressing cells.
Overexpression of FUT4 increased the invasive ability of 
the MCF-7 cells in vitro (Fig. 2C). In order to further confirm 
that FUT4 affects invasive ability, we used shRNA delivered 
in a lentiviral vector tagged with GFP to regulate FUT4 
expression in the MDA-MB-231 cells. Three different shRNA 
lentiviruses significantly reduced the FUT4 expression >60% at 
the mRNA level and >50% at the protein level (Fig. 3A and B). 
The invasive ability was significantly decreased to 55% in the 
MDA-MB-231/FUT4-shRNA cells compared with the inva-
sive ability noted in the control cells (Fig. 3C).
In order to identify whether FUT4 further affects the 
tumorigenicity in vivo, MCF-7/control, MCF-7/FUT4, 
MDA-MB-231/cont rol shRNA and MDA-MB-231/
FUT4-shRNA1 were subcutaneously injected into nude mice 
and tumor formation was monitored. On day 28, the mice were 
sacrificed under anesthesia and tumor weights were measured. 
Tumors grew faster in the MCF-7/FUT4 and MDA-MB-231/
control shRNA groups when compared with the rates in the 
MCF-7/control and MDA-MB-231/FUT4-shRNA1 groups, 
respectively (Figs. 2D and 3D). These data suggest that FUT4 
enhanced the cell growth in vivo.
Differential expression of miR-493-5p in breast cancer cell 
lines and tissues. To understand the mechanisms by which 
Figure 1. Differential expression of the FUT4 gene in human breast cancer cell lines and tissues. (A and B) The levels of FUT4 were analyzed in breast cancer 
cell lines (MCF-7 and MDA-MB-231) via real-time PCR and western blotting. Increase in FUT4 was observed in the MDA-MB-231 cells. (C and D) The levels 
of FUT4 were analyzed in tissues. The primary breast cancer tissues expressed higher expression of FUT4 both at the mRNA and protein levels than levels in 
the matched adjacent tissue samples (*P<0.05). Data are the mean ± SD of triplicate determinants.
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Figure 2. Effect of overexpression of FUT4 on the invasive ability and tumorigenicity of breast cancer cells in vitro and in vivo. (A) Overexpression of 
FUT4 in cells was analyzed following transfection of lentiviral vectors containing FUT4. FUT4 was detected by RT-PCR after lentiviral vector transfection. 
(B) Expression of the FUT4 protein was detected by western blotting. (C) The average number of cells that invaded through the filter was counted by ECMatrix 
gel analysis. (D) The growth curves of tumors after injection of MCF-7/control and MCF-7/FUT4 cells in nude mice (*P<0.05). Tumor sizes were measured 
every 7 days during a 28-day period. Data are the mean ± SD of triplicate determinants.
Figure 3. Effects of the silencing of FUT4 on the invasiveness and tumorigenicity of breast cancer cells in vitro and in vivo. (A) The mRNA level of FUT4 was 
investigated by RT-PCR after shRNA transfection. (B) Expression of the FUT4 protein was detected by western blotting. (C) In vitro ECMatrix gel analysis 
was performed. (D) Tumor volumes were measured every 7 days during the 28-day period (*P<0.05). Data are the mean ± SD of triplicate determinants.
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miRNAs execute their function by FUT4, we adopted 3 bioin-
formatic algorithms (TargetScan, MicroCosm and miRanda) 
to identify a large number of potential miRNAs. Among these 
candidates, miR-493-5p was selected for further study. Total 
RNA was isolated from the cell lines, the breast cancer tissue 
and the matched adjacent tissue samples, and the miR-493-5p 
levels were determined using TaqMan real-time PCR. The 
miR-493-5p expression level was higher in the MCF-7 cells 
than that in the MDA-MB-231 cells, while the tissue samples 
showed the same tendency (Fig. 4A and B).
miR-493-5p directly targets and inhibits FUT4 expression. To 
test whether FUT4 is a direct target of miR-493-5p, luciferase 
activity assays were performed using luciferase reporters. The 
3'-untranslated region (3'-UTR) of the FUT4-mRNA, which 
contains a predicted target site for miR-493-5p, was cloned into 
the GP-miRGLO plasmid. In addition, 3 nucleotides within 
the predicted miR-493-5p target site were mutated in the 
GP-miRGLO-FUT4-3'-UTR mutant plasmid. When the 3'-UTR 
of the FUT4 mRNA was involved in the luciferase transcript, 
forced miR-493-5p expression decreased luciferase activity 
by 35% (Fig. 5A), whereas, miR‑493‑5p mimics had no effect 
on the luciferase activity of the reporters containing a mutant 
FUT4 3'-UTR. The results indicated that miR-493-5p targeted 
the 3'-UTR of the FUT4 mRNA and repressed its expression.
To determine whether FUT4 expression is indeed regu-
lated by miR-493-5p in vitro, the MDA-MB-231 cells were 
transfected with miR-493-5p agomir, while the MCF-7 cells 
were transfected with the miR-493-5p antagomir. As expected, 
miR-493-5p agomir-treated cells showed higher expression of 
miR-493-5p, and miR-493-5p antagomir inhibited miR-493-5p 
expression (Fig. 5B and E). The MDA-MB-231 cell line with 
miR‑493‑5p expression showed a significant attenuation of 
FUT4 expression at both the mRNA and protein levels in vitro. 
Moreover, inhibition of miR-493-5p in MCF-7 cells led to the 
opposite changes in FUT4 expression (Fig. 5C, D, F and G).
miR-493-5p attenuates the invasiveness in vitro and the 
tumorigenicity in human breast cancer by targeting FUT4 
in vivo. Since the expression levels of miR-493-5p were lower 
in the MDA-MB-231 cells and breast cancer tissues when 
compared with the levels in MCF-7 cells and matched adjacent 
tissues, we examined how alterations in miR‑493‑5p influence 
metastatic behavior. MCF-7 and MDA-MB-231 cells were 
transfected with antagomir or agomir of miR-493-5p, respec-
tively. The effects of the antagomir and the agomir on the 
invasive rate of MDA-MB-231 and MCF-7 cells were studied 
with Transwell assay (Fig. 6A and B). Forced miRNA-493-5p 
overexpression resulted in 41% reduction in the invasive 
potential of the MDA-MB-231 cells compared to the control 
cells. The invasive potential was increased in the MCF-7 cells 
transfected with the antagomir. The enhanced expression of 
FUT4 significantly increased or reversed the invasive capabili-
ties of the MCF-7 cells (Fig. 6F and G).
To ascertain whether miR-493-5p could further affect 
the tumorigenicity in vivo, MDA-MB-231, MDA-MB-231/
NC and MDA-MB-231/agomir cells were injected into nude 
mice and tumor formation was monitored. The tumor volume 
in the MDA-MB-231/agomir group was decreased compared 
to that noted in the MDA-MB-231 and MDA-MB-231/NC 
groups (Fig. 6C). Downregulation of FUT4 was also observed 
in the MDA-MB-231/agomir group (Fig. 6D and E).
Discussion
Changes in fucosylation can be observed in nearly all malig-
nancies, such as breast (16), hCC (17), colon (18) and lung 
cancer (19). high incidence of sLex in ER-negative breast 
tumors coincided with high expression of glycosyltransfer-
ases FUT3, FUT4 and ST3GAL6 (20). Previous studies have 
demonstrated a significant high expression of FUT4 in breast 
cancer tissues and sera in comparison to normal tissues and 
sera (21). The present study revealed that the expression profile 
of the FUT4 gene varied between MDA-MB-231 and MCF-7 
cell lines with different metastatic potential. Compared to the 
MCF-7 cells, MDA-MB-231 cells showed upregulated expres-
sion of FUT4 (5.76-fold). Comparison of FUT4 expression 
levels in 29 pairs of clinical primary breast cancer tissues and 
their matched adjacent tissues revealed that FUT4 was upregu-
lated in the primary breast cancer tissues. FUT4 with different 
Figure 4. Differential expression of miR-493-5p in breast cancer cell lines and tissues. (A) A comparison of miR-493-5p expression between the primary breast 
cancer and the matched adjacent tissue samples. (B) The expression of miR-493-5p was examined by real-time PCR in MDA-MB-231 and MCF-7 cells. U6 was 
included as a control. The miR-493-5p expression was higher in MCF-7 cells than that in the MDA-MB-231 cells, while miR-493-5p was decreased in primary 
breast cancer tissues in comparison to the matched adjacent tissues (*P<0.05). Data are the mean ± SD of triplicate determinants.
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expression patterns in the two cell lines and breast cancer 
tissues imply its role as an indicator and functional regulator 
of breast cancer metastasis.
A previous study found that stable transfection of antisense 
sequences directed at the human Lewis α (1,3/1,4) FUT gene, 
FUT3 led to the inhibition of E-selectin-mediated adenocar-
cinoma cell adhesion (22). Elevated expression of FUT3/6 
conferred increased sLex production. sLex+ cells (with high 
FUT expression levels) were significantly more invasive than 
sLex- cells (with low FUTs). This suggests an association 
between FUT expression and invasive activity. Inactivation 
of the expression of FUT1 and FUT2 reduced cell adhesion 
efficiency and inhibited cell growth (23). FUT6, a member of 
the a1,3/4 FUT subfamily, was found to regulate the P13K/
AKT signaling pathway in hCC cells (24). Whether the FUT4 
and its encoded protein affect tumor invasion, proliferation 
and tumorigenicity in breast cancer remains a question. The 
present study aimed to explore FUT4. The altered level of 
FUT4 led to mediated invasiveness and tumorigenicity in 
MCF-7 and MDA-MB-231 cell lines both in vitro and in vivo. 
Taken together, these data suggest that fucosylation is closely 
related to the activities of invasion and proliferation in breast 
cancer cells.
MicroRNAs (miRNAs) are attractive candidates as 
upstream regulators of metastatic progression since miRNAs 
can post-transcriptionally regulate entire sets of genes (25,26). 
Figure 5. FUT4 is a target gene of miR-493-5p. (A) Dual-luciferase reporter assays were performed by pmir-reporter constructs containing the FUT4 3'-UTR 
region with the seed sequences or a mutated sequence that was inserted downstream of the luciferase coding sequence. Transfection with a miR-493-5p mimic 
decreased luciferase activity of the reporter vector containing the 3'-UTR of a wild-type FUT4 (*P<0.05). (B and E) Expression of miR-493-5p was examined 
after transfection of MDA-MB-231 and MCF-7 cells with miR-493-5p agomir, miR-493-5p agomir control, miR-493-5p antagomir or miR-493-5p antagomir 
control. (C and F) The mRNA of FUT4 was detected by RT-PCR in cells treated with the agomir or antagomir (*P<0.05). (D and G) The protein levels of the 
FUT4 protein were detected by western blotting (*P<0.05). Data are the mean ± SD of triplicate determinants.
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Figure 6. miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4 both in vitro and in vivo. (A) Knockdown of 
miR-493-5p increased the invasive ability of the MCF-7 cells (*P<0.05). (B) Overexpression of miR-493-5p decreased the invasive ability of MDA-MB-231 
cells (*P<0.05). (C) Tumor volume was assessed every 7 days. (D and E) The expression levels of FUT4 in nude mice were analyzed by western blotting and 
immunohistochemistry. Reduced immunohistochemistry staining against FUT4 was found in the MDA-MB-231/agomir group, compared to the MDA-MB-
231/NC group. (F) MCF-7/control and MCF-7/FUT4 cells were respectively transfected with the miR-493-5p agomir or agomir control. Western blotting 
showed that MCF-7/FUT4 cells transfected with the miR-493-5p agomir blocked miR-493-5p-induced suppression of FUT4 protein expression. (G) Invasion 
assays indicated that FUT4 restoration abolished miR-493-5p-induced suppression of invasion and metastasis in MCF-7/FUT4 cells after transfection with the 
miR-493-5p agomir. The results are expressed as mean ± SD of 3 independent experiments (*P<0.05).
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Recent research has revealed the vital roles of miRNAs in 
tumorigenesis (27,28). miRNAs often act as oncogenes or tumor 
suppressors, regulating many cellular processes. miR-335 was 
found to suppress metastasis and migration through targeting 
of the progenitor cell transcription factor SOX4 and extra-
cellular matrix component tenascin C (29). A few miRNAs 
have been identified to target glycosylation enzymes to date. 
miR-378 targeted UDP-N-acetyl-D-galactosamine: polypep-
tide N-acetylgalactosaminyltransferase 7 and enhanced the 
glycosylation of nephronectin, a ligand for integrin α8β1 (30). 
miR-148 targeted the enzyme core 1 β1, 3-galactosyltrans-
ferase 1 and modulated IgA1 O-glycosylation and the level 
of secreted galactose‑deficient IgA1 (31). miR‑199a targeted 
the glycosylation enzyme ST6GAL1, reduced the sialylation 
of Necl-2, indirectly reduced the protein level of Necl-2, and 
enhanced ErbB2/ErbB3 signaling (32). It was reported that 
miR-493 inhibited the formation of metastatic foci and thus 
prevented liver metastasis of colon cancer cells (33). miR-493, 
was found to be reduced in lung cancer cells and tissues and to 
suppress cell invasion and proliferation by blocking E2F1 (34). 
miR-493 inhibited cell invasion and migration by blocking 
FZD4 and RhoC in bladder cancer (35).
miR-493-5p is prominently upregulated in male breast 
cancer (36). however, miR-493, as analyzed by NanoString's 
nCounter human miRNA expression profiling, was down-
regulated in TNBCs vs. normal breast tissues (37). The role 
of miR-493-5p remains unclear in breast cancer cell lines and 
in breast cancer at present. In the present study, we showed 
that the level of miR-493-5p, a potentially candidate tumor-
suppressor miRNA, was low in MDA-MB-231 cells and breast 
cancer tissues. Introduction of miR-493-5p into MDA-MB-231 
cells resulted in a reduction in tumor cell invasion and tumori-
genicity. Furthermore, miR-493-5p was found to target the 
3'-UTR of FUT4, causing decreased FUT4 expression at the 
mRNA and protein levels, thus controlling the invasiveness of 
breast cancer cells. This result indicated that miR-493-5p may 
serve as a specific modulator of human breast cancer invasion 
and tumorigenicity through targeting FUT4.
In summary, the FUT4 gene was demonstrated to regulate 
the invasiveness and tumorigenicity of human breast cancer. 
The aberrant expression of miR-493-5p was associated with 
breast cancer invasiveness and tumorigenicity. Moreover, we 
found that miR-493-5p targeted the 3'-UTR of FUT4 mRNA 
and reduced the protein expression level of FUT4. Our results 
provide new insight into the mechanisms underlying the inva-
sion and tumorigenicity of breast cancer, and the application 
of miR-493-5p may be a potential strategy for breast cancer 
therapeutics.
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